{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Brainstorm Cell Therapeutics, Inc.
Is Brainstorm Cell Therapeutics, Inc. technically bullish or bearish?
As of June 4, 2025, the market trend is mildly bearish, influenced by daily moving averages and Bollinger Bands, while mixed signals from the weekly MACD and KST suggest some mild bullishness amidst an overall weak bearish sentiment.
Who are in the management team of Brainstorm Cell Therapeutics, Inc.?
As of March 2022, the management team of Brainstorm Cell Therapeutics, Inc. includes Prof. Jacob Frenkel (Chairman), Dr. Irit Arbel (Vice Chairman), Mr. Uri Yablonka (Executive VP, Chief Business Officer), and several independent directors. They oversee the company's strategic direction and operations.
What does Brainstorm Cell Therapeutics, Inc. do?
Brainstorm Cell Therapeutics, Inc. is a biotechnology company focused on developing adult stem cell therapies for neurodegenerative disorders like ALS, MS, and Parkinson's disease. It has a market cap of $9.48 million and reported a net profit loss of $3 million as of March 2025.
How big is Brainstorm Cell Therapeutics, Inc.?
As of Jun 18, Brainstorm Cell Therapeutics, Inc. has a market capitalization of 9.48 million, with net sales of 0.00 million and a net profit of -11.08 million over the last four quarters. The company's shareholder's funds are -7.76 million, and total assets are 1.83 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
